1. Pink Sheet

Congressional Action On Drug Pricing Blueprint Likely To Be Modest

 
• By Michael Cipriano

Senate Health, Education, Labor and Pensions Committee Chair Lamar Alexander noted panel's lack of consensus on drug pricing policies advanced by the Trump Administration during June 12 hearing.

Washington DC Capitol dome detail with waving american flag

The first US congressional committee hearing on the Trump Administration’s blueprint for lowering drug prices suggests that legislation is possible on a modest suite of reforms but that the most impactful changes may come from administrative action.

During the June 12 hearing in the Senate Health, Education, Labor and Pensions Committee, Health and Human Services (HHS) Secretary...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

More from Market Access

UK MHRA: Bacteriophage Developers Wanted ‘More Clarity’ On UK Framework

 
• By Eliza Slawther

Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.

Respiratory Treatments Hit Hardest By HTA Terminations In England

 
• By Leela Barham

Exclusive analysis by the Pink Sheet explores how non-submissions by pharmaceutical companies to England’s health technology appraisal body are impacting the availability of medicines on the National Health Service.

New Pricing Agreements And Greater Transparency: What A US MFN Policy Could Mean For France

 
• By Francesca Bruce

A potential MFN drug pricing policy in the US could also lead to a greater push for collaborative action in the EU, such as joint procurement among the member states, says one European industry expert.